Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856917 | 0.94 | — | — | |
| SCHEMBL19634468 | 0.71 | MEN1 (0.36) | SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL19226221 | 0.70 | PSEN1 (0.32) | ANPEPERAP2 | |
| SCHEMBL15541721 | 0.70 | SMN1; SMN2 (0.38) | HSD17B10SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL342302 | 0.70 | SMN1; SMN2 (0.38) | HSD17B10SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL341318 | 0.67 | SMN1; SMN2 (0.34) | HSD17B10SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL372303 | 0.66 | SIGMAR1 (0.36) | SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL7477423 | 0.66 | ANPEP (0.48) | ANPEPERAP2HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL30785507 | 0.65 | TDP1 (0.36) | HSD17B10SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL24891399 | 0.65 | HRH3 (0.39) | SMN1; SMN2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | ANPEP 3896/4885ERAP2 2997/4885HSD17B10 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.